



PRE-MEETING WORKSHOP

IMMUNE EFFECTOR CELL (IEC)
THERAPIES

MAY 15, 2022



IMMUNE EFFECTOR CELL (IEC) THERAPIES


SUNDAY, MAY 15, 2022

All times listed below ET

Co-chairs: Catherine Bollard, MD
Stephen Gottschalk, MD

Description

The Immune Effector Cell (IEC) Therapies Workshop will feature discussions of the current state of IEC therapeutic approaches with updates on IEC-related toxicities, new directions in T cell engineering specificities and new generation CAR-T cell therapies.





IMMUNE EFFECTOR CELL (IEC) THERAPIES

Schedule

All times listed below ET

1:00–1:20 PM

Lymphoma Derived From PiggyBac-Modified CD19 CAR-T Cell Therapy

*David Bishop, BMedSc(Hons), MBBS, PhD, FRACP, FRCPA,
The University of Sydney, Westmead Hospital*



Join our symposium:

*State-of-the-art closed system
manufacturing of cell and gene therapy
products with the CliniMACS Prodigy®*

Wednesday, May 18, 12:00 p.m. – 1:30 p.m. (ET)
ASGCT Room 207

Join Miltenyi Biotec as we share our latest developments
from the evolving field of cell and gene therapy.

Ian Johnston, PhD

Industrial and Academic Cooperations Manager
Senior Project Manager

Kunal Patel, MS

Manager, Process Engineering

► **[miltenyibiotec.com](https://www.miltenyibiotec.com)**

Miltenyi Biotec, Inc. | 6125 Cornerstone Court East | San Diego, CA 92121, USA
Phone 800 FOR MACS | macs@miltenyibiotec.com | www.miltenyibiotec.com

Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. CliniMACS Prodigy is a registered trademark of Miltenyi Biotec and/or its affiliates in various countries worldwide. All other trademarks are the property of their respective owners.

Copyright © 2022 Miltenyi Biotec and/or its affiliates. All rights reserved.



Miltenyi Biotec

IMMUNE EFFECTOR CELL (IEC) THERAPIES

1:20–1:40 PM

PSMA-Directed/TGF β -Insensitive CAR-T Cell Therapy

Naomi Haas, MD, University of Pennsylvania, Abramson Cancer Center

1:40–2 PM

CarHLH - An Initially Overlooked Complication of CAR-T Cell Therapy

*Nirali N. Shah, MD, MHSc, National Cancer Institute,
National Institutes of Health*

2:10–2:30 PM

Peptide-Centric CAR-T Cells to Target Intracellular Antigens

John Maris, MD, Children's Hospital of Philadelphia, PA

2:30–2:50 PM

TruCs: An Alternative Synthetic T Cell Receptor

Robert Hofmeister, PhD, TCR2 Therapeutics

2:50–3:10 PM

Gene Editing to Improve CAR-T Cell Therapy

Giedre Krenciute, PhD, St. Jude Children's Research Hospital

3:40–4:00 PM

Modulating CAR Signaling to Prevent or Reverse Exhaustion

Evan Weber, PhD, Stanford University School of Medicine



IMMUNE EFFECTOR CELL (IEC) THERAPIES

4:00–4:20 PM

Transcriptional Engineering of CD8 TILs

Patrick G. Hogan, PhD, La Jolla Institute for Immunology

4:20–4:40 PM

Engineering CAR T Cells With Improved Effector Function

Barbara Savoldo, MD, PhD, University of North Carolina at Chapel Hill



THANK YOU

25TH ANNUAL MEETING SPONSORS



Miltenyi Biotec

